Abiomed's Impella(R) Technology Showcased at TCT 2012 With Over 25 Scheduled Presentations in the Scientific SessionsDANVERS, Mass., Oct. 15, 2012 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be over 25 Impella presentations in the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2012 scientific meeting, scheduled from October 22 - 26, at the Miami Beach Convention Center in Miami, FL.
"We are excited to see that there are over 25 potential Impella-related presentations listed in the program for TCT scientific sessions this year, the largest number ever," said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed.
On the TCT show floor, Abiomed will conduct daily booth demonstrations at Abiomed booth #808 and hands-on simulations of the Impella platform.
For further information about the TCT scientific program and the timing of scientific presentations, please contact Aimee Genzler, Corporate Communications Manager, at [email protected] or 978-646-1553.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
The Abiomed logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13564
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
